Tim Cripe, MD, PhD
Academic Title: Professor in the College of Medicine
Research Program: Translational Therapeutics
Columbus, Ohio 43205
About Me
More info forI am a professor of Pediatrics at The Ohio State University, chief of the Division of Hematology/Oncology/BMT at Nationwide Children's Hospital, and a member of the Translational Therapeutics Program at the OSUCCC – James. My research centers on the development and clinical translation of immuno-gene therapy for cancer, with the aim of improving patient outcomes and reducing side effects of treatment.
In my laboratory, my team and I are focused on the development and testing of virus-based cancer immunotherapeutics. Our flagship development achieves the same desired results as CAR-T cells with long lasting effects after a single dose, but doesn't require conditioning chemotherapy, and may be safer and more effective.
We are developing a series of similar therapeutics that target various cancers in both children and adults, including lymphoblastic leukemia, multiple myeloma, neuroblastoma and different sarcomas. The immune system is the most powerful "drug" in the world, and the opportunity to harness it to better fight cancer is exciting.
It’s a privilege to be able to utilize research advancements to enhance my clinical work. I am passionate about ensuring our patients have access to the most innovative therapy options, and I strongly advocate for my patients to ensure they have the best experience possible. Taking care of patients with cancer allows me to go on a long journey with them and their families, and it’s an honor to get to know and learn from them.
Seeing my patients face one of life's greatest challenges with grace and dignity is awe-inspiring. When we are successful, I am gratified to watch them thrive as they progress through life's milestones. As we continue to increase our understand of the science underlying cancer biology, we can continue to develop novel treatments. This work gives me hope for a better future.
In addition to my clinical and research responsibilities, I am the co-founder and board member of Vironexis Biotherapeutics, Inc., established with the purpose of bringing immuno-gene therapy to patients. I also served as chair of the Cellular, Tissue and Gene Therapies Advisory Committee at the Food and Drug Administration.
I have co-authored more than 100 articles and book chapters. The articles have appeared in well-respected publications such as the Journal of Clinical Investigation, Cancer Research, Clinical Cancer Research, Molecular Therapy and the Journal of Clinical Oncology.
Research Interests
More info for- Immunotherapy
- Tumor Associated Macrophages
- Sarcoma
- Therapeutics
- Infection
- Genetic Therapy
- Neuroblastoma
- Neurofibroma
- Neoplasms
- Tumor Microenvironment
- Neurilemmoma
- Neurofibromatosis 1
- T-Lymphocytes
- Sarcoma, Ewing
- Osteosarcoma
- Rhabdomyosarcoma
- Pediatrics
Academic Office & Contact Information
More info forAcademic Office:
Children's Hospital - Educatio
700 Childrens Dr
Columbus, Ohio 43205Phone:
614-722-3521Publications
More info forSeptember 12, 2024Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy.
Luo W, Hoang H, Zhu H, Miller K, Mo X, Eguchi S, Tian M, Liao Y, Ayello J, Rosenblum JM, Marcondes M, Currier M, Mardis E, Cripe T, Lee D, Cairo MS
J Immunother Cancer
July 11, 2024Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning "Two Keys" simultaneously.
Luo W, Hoang H, Miller KE, Zhu H, Xu S, Mo X, Garfinkle EAR, Costello H, Wijeratne S, Chemnitz W, Gandhi R, Liao Y, Ayello J, Gardenswartz A, Rosenblum JM, Cassady KA, Mardis ER, Lee DA, Cripe TP, Cairo MS
J Exp Clin Cancer Res
June 20, 2024Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts.
Chu Y, Nayyar G, Tian M, Lee DA, Ozkaynak MF, Ayala-Cuesta J, Klose K, Foley K, Mendelowitz AS, Luo W, Liao Y, Ayello J, Behbehani GK, Riddell S, Cripe T, Cairo MS
Mol Ther Oncol
May 30, 2024Disease Control and Toxicity Outcomes after Stereotactic Ablative Radiation Therapy for Recurrent and/or Metastatic Cancers in Young-Adult and Pediatric Patients.
Upadhyay R, Klamer B, Matsui J, Chakravarthy VB, Scharschmidt T, Yeager N, Setty BA, Cripe TP, Roberts RD, Aldrink JH, Singh R, Raval RR, Palmer JD, Baliga S
Cancers (Basel)
March 21, 2024Progress in sarcomas: Highlights from the 2023 annual meetingof the Connective Tissue Oncology Society.
Cripe TP, Roberts RD, Chandler DS, Setty BA, Chen S, Shenoy A, Venkataramany AS, Ringwalt EM, Scharschmidt T, Utset-Ward T, Konieczkowski DJ, Grignol VP, Beane JD, Ruff SM, Pollock RE
Mol Ther Oncol
January 1, 2024Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy.
Kim Y, Saini U, Kim D, Hernandez-Aguirre I, Hedberg J, Martin A, Mo X, Cripe TP, Markert J, Cassady KA, Dhital R
Front Immunol
January 1, 2024Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.
Paudel SN, Hutzen BJ, Miller KE, Garfinkle EAR, Chen CY, Wang PY, Glaspell AM, Currier MA, Ringwalt EM, Boon L, Mardis ER, Cairo MS, Ratner N, Dodd RD, Cassady KA, Cripe TP
Front Immunol
January 1, 2024Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.
Paudel SN, Hutzen BJ, Miller KE, Garfinkle EAR, Chen CY, Wang PY, Glaspell AM, Currier MA, Ringwalt EM, Boon L, Mardis ER, Cairo MS, Ratner N, Dodd RD, Cassady KA, Cripe TP
Front Immunol
September 21, 2023Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution.
Hedberg J, Studebaker A, Smith L, Chen CY, Westfall JJ, Cam M, Gross A, Hernandez-Aguirre I, Martin A, Kim D, Dhital R, Kim Y, Roberts RD, Cripe TP, Mardis ER, Cassady KA, Leonard J, Miller KE
Mol Ther Oncolytics
September 21, 2023The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?
Paudel SN, Hutzen B, Cripe TP
Mol Ther Oncolytics
July 28, 2023Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment.
Canella A, Nazzaro M, Rajendran S, Schmitt C, Haffey A, Nigita G, Thomas D, Lyberger JM, Behbehani GK, Amankulor NM, Mardis ER, Cripe TP, Rajappa P
Cell Rep
December 5, 2022Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors.
Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, Rajappa P
J Neuroimmunol
December 1, 2022An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors.
Abdelbaki MS, DeWire Schottmiller MD, Cripe TP, Curry RC, Cruze CA, Her L, Demko S, Casey D, Setty B
Heliyon
July 15, 2022Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics.
Cripe TP, Hutzen B, Currier MA, Chen CY, Glaspell AM, Sullivan GC, Hurley JM, Deighen MR, Venkataramany AS, Mo X, Stanek JR, Miller AR, Wijeratne S, Magrini V, Mardis ER, Mendell JR, Chandler DS, Wang PY
Sci Adv
March 23, 2022Alternative RNA Splicing Defects in Pediatric Cancers: New Insights in Tumorigenesis and Potential Therapeutic Vulnerabilities.
Venkataramany AS, Schieffer KM, Lee K, Cottrell CE, Wang PY, Mardis ER, Cripe TP, Chandler DS
Ann Oncol
January 24, 2022Clinical outcomes and efficacy of stereotactic body radiation therapy in children, Adolescents, and Young Adults with Metastatic Solid Tumors.
Baliga S, Matsui J, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty BA, Roberts RD, Olshefski RS, Cripe TP, Scharschmidt TJ, Aldrink J, Mardis E, Yeager ND, Palmer JD
Br J Radiol
November 25, 2021Immunotherapies for Pediatric Solid Tumors: A Targeted Update.
Gupta A, Cripe TP
Paediatr Drugs
November 1, 2021Clinical Outcomes and Efficacy of Stereotactic Body Radiation Therapy in Metastatic Pediatric Solid Tumors.
Baliga S, Matsui JK, Klamer B, Cetnar A, Ewing A, Cadieux C, Gupta A, Setty B, Roberts R, Cripe TP, Scharschmidt T, Aldrink J, Mardis ER, Yeager ND, Olshefski R, Palmer JD
Int J Radiat Oncol Biol Phys
October 1, 2021Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy.
Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA
J Immunother Cancer
July 23, 2021Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma.
Wedekind MF, Miller KE, Chen CY, Wang PY, Hutzen BJ, Currier MA, Nartker B, Roberts RD, Boon L, Conner J, LaHaye S, Kelly BJ, Gordon D, White P, Mardis ER, Cripe TP
iScience
October 1, 2020Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma.
Lipschitz N, Earl BR, Cripe TP, Samy RN
Curr Opin Otolaryngol Head Neck Surg
September 22, 2020Gene Editing Thumbs a Ride with Oncolytic Virotherapy.
Wang PY, Cripe TP
Mol Ther
June 18, 2020Pediatric cancer research: Surviving COVID-19.
Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP
Pediatr Blood Cancer
April 8, 2020Drug targeting the actin cytoskeleton potentiates the cytotoxicity of low dose vincristine by abrogating actin-mediated repair of spindle defects.
Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW
Mol Cancer Res